Progress in Immunotherapy for Squamous Non-small Cell Lung Cancer

by Shouzheng WANG, Junling LI
Published 2016-10-01

Analysis of the Correlation between Molecular Structural Differences of PD-1/PD-L1 Inhibitors and Adverse Events

by Tongji XIE, Shouzheng WANG, Puyuan XING
Published 2020-07-01

Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations

by Shouzheng Wang, Puyuan Xing, Ke Yang, Xuezhi Hao, Di Ma, Yuxin Mu, Junling Li
Published 2019-06-01

Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma

by Shouzheng Wang, Tongji Xie, Xuezhi Hao, Yan Wang, Xingsheng Hu, Lin Wang, Yan Li, Junling Li, Puyuan Xing
Published 2021-10-01

Exploration of the Tumor-Suppressive Immune Microenvironment by Integrated Analysis in EGFR-Mutant Lung Adenocarcinoma

by Teng Li, Xiaocong Pang, Junyun Wang, Junyun Wang, Shouzheng Wang, Yiying Guo, Ning He, Puyuan Xing, Junling Li
Published 2021-05-01

Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis

by Puyuan Xing, Fan Zhang, Guoqiang Wang, Yu Xu, Chengcheng Li, Shouzheng Wang, Yiying Guo, Shangli Cai, Yan Wang, Junling Li
Published 2019-12-01